Diamedica Therapeutics Inc (DMAC)

Dec 3, 2024, 8:25 AM EST - 6 weeks ago

DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia

Nov 14, 2024, 12:49 PM EST - 2 months ago

DiaMedica Therapeutics Inc. (DMAC) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 4:20 PM EST - 2 months ago

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results

Nov 13, 2024, 4:05 PM EST - 2 months ago

DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia

Nov 12, 2024, 8:23 AM EST - 2 months ago

DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference

Nov 6, 2024, 8:32 AM EST - 2 months ago

DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024

Oct 9, 2024, 8:27 AM EDT - 3 months ago

DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia

Sep 4, 2024, 4:15 PM EDT - 4 months ago

DiaMedica Therapeutics Upcoming Conference Participation

Aug 7, 2024, 4:15 PM EDT - 5 months ago

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results

Aug 1, 2024, 8:20 AM EDT - 6 months ago

DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024

Jul 11, 2024, 2:48 PM EDT - 6 months ago

DiaMedica: Early 2025 Interim Futility Analysis Could Be A Major Inflection Point

Jul 11, 2024, 8:00 AM EDT - 6 months ago

DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

Jul 1, 2024, 8:00 AM EDT - 7 months ago

DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement

Jun 26, 2024, 8:15 AM EDT - 7 months ago

DiaMedica Therapeutics Announces $11.8 Million Private Placement

Jun 26, 2024, 8:00 AM EDT - 7 months ago

DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia

May 11, 2024, 4:49 PM EDT - 9 months ago

DiaMedica Therapeutics Inc. (DMAC) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:30 PM EDT - 9 months ago

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results

May 2, 2024, 8:55 AM EDT - 9 months ago

DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024

Apr 17, 2024, 4:08 PM EDT - 9 months ago

DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke

Mar 20, 2024, 4:14 PM EDT - 10 months ago

DiaMedica Therapeutics Inc. (DMAC) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 4:15 PM EDT - 10 months ago

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results

Jan 29, 2024, 4:13 PM EST - 1 year ago

DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference

Jan 22, 2024, 8:23 AM EST - 1 year ago

DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

Nov 14, 2023, 12:10 PM EST - 1 year ago

DiaMedica Therapeutics Inc. (DMAC) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 4:28 PM EST - 1 year ago

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results

Nov 9, 2023, 8:25 AM EST - 1 year ago

DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023

Nov 6, 2023, 8:23 AM EST - 1 year ago

DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023

Sep 12, 2023, 8:13 AM EDT - 1 year ago

DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer

Sep 6, 2023, 8:35 AM EDT - 1 year ago

DiaMedica Therapeutics to Participate at Lake Street's 7th Annual Best Ideas Growth Conference

Aug 15, 2023, 3:43 PM EDT - 1 year ago

DiaMedica Therapeutics Inc. (DMAC) Q2 2023 Earnings Call Transcript

Aug 14, 2023, 4:13 PM EDT - 1 year ago

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results

Aug 8, 2023, 8:32 AM EDT - 1 year ago

DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023

Jul 18, 2023, 8:30 AM EDT - 1 year ago

DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference

Jun 26, 2023, 8:30 AM EDT - 1 year ago

DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement

Jun 21, 2023, 8:39 AM EDT - 1 year ago

DiaMedica Therapeutics Announces $37.5 Million Private Placement

Jun 21, 2023, 8:15 AM EDT - 1 year ago

DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke

May 30, 2023, 8:29 AM EDT - 1 year ago

DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors

MDT

May 16, 2023, 9:11 AM EDT - 1 year ago

DiaMedica Therapeutics Inc. (DMAC) Q1 2023 Earnings Call Transcript

May 15, 2023, 4:28 PM EDT - 1 year ago

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial Results

May 8, 2023, 8:50 AM EDT - 1 year ago

DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023

Apr 11, 2023, 8:41 AM EDT - 1 year ago

DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer

Mar 29, 2023, 10:01 AM EDT - 1 year ago

DiaMedica Therapeutics Inc. (DMAC) Q4 2022 Earnings Call Transcript

Mar 28, 2023, 4:30 PM EDT - 1 year ago

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2022 Financial Results

Mar 20, 2023, 4:17 PM EDT - 1 year ago

DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023

Mar 13, 2023, 8:00 AM EDT - 2 years ago

DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 6, 2023, 8:30 AM EST - 2 years ago

DiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of Directors

Nov 9, 2022, 4:15 PM EST - 2 years ago

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2022 Financial Results

Nov 7, 2022, 8:32 AM EST - 2 years ago

DiaMedica Therapeutics to Attend the 13th Annual Craig-Hallum Alpha Select Conference November 17, 2022

Oct 31, 2022, 8:32 AM EDT - 2 years ago

DiaMedica Therapeutics to Present at Credit Suisse 31st Annual Healthcare Conference

Oct 26, 2022, 4:30 PM EDT - 2 years ago

DiaMedica Therapeutics Provides Update on ReMEDy2 Trial